Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion ...

Since 1972, shares of Eli Lilly have generated a total return north of 100,000%. Clearly, Lilly has been a consistent ...

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's ...

Eli Lilly and Company is expanding its manufacturing footprint in Ireland with a $1.8B investment to boost production of ...

Lucas Montarce's career path at the company is similar to that of his predecessor, Anat Ashkenazi.

Chicago, IL – September 12, 2024 – Zacks Equity Research shares Eli Lilly LLY as the Bull of the Day and Hertz Global HTZ as ...

Company ups manufacturing investment in Limerick by $1 billion; unveils new $800 million Kinsale facility New investment will enhance global medicine production, benefiting millions of patients ...

Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective ...

This additional investment is part of Eli Lilly's most ambitious manufacturing expansion agenda in the company’s history.